Celularity Inc.
1.9300-0.07 (-3.5%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · CELU · USD
Key Stats
Market Cap
51.51MP/E (TTM)
-Basic EPS (TTM)
-3.18Dividend Yield
0%Recent Filings
8-K
8-K
Nasdaq compliance confirmed
Celularity Inc. received Nasdaq notice on September 2, 2025, confirming compliance with Listing Rule 5250(c)(1) based on its recent 10-Q filings for quarters ended March 31 and June 30, 2025. The determination, stemming from the August 29, 2025 submissions, resolves prior concerns over financial reporting. Nasdaq delisting risk averted. This bolsters investor confidence amid ongoing operations.
10-Q
Q1 FY2025 results
Celularity's Q1 FY2025 revenues dipped 22.2% y/y to $11.4M, with product sales down 29.8% y/y to $9.0M from softer Biovance 3L demand, yet services rose 9.4% y/y to $1.4M and license/royalty climbed 81.5% y/y to $1.0M. Gross margins narrowed as costs surged 117% y/y to $3.6M, driven by a $0.7M Interfyl write-off and product mix shifts, yielding an operating loss of $10.5M, up 42.2% y/y. Operating loss outpaced net loss of $19.8M (vs. $22.0M y/y), with the gap widened by $5.7M debt extinguishment and $2.4M interest, offset by a $0.2M warrant fair-value gain. Cash burned $3.0M in operations, ending at $0.3M amid $43.1M debt (mostly related-party, under forbearance); FCF not disclosed in the 10-Q. Acquired Rebound assets in Oct 2024 for $1.0M upfront plus up to $4.0M milestones (20% of net sales), recognizing $2.2M inventory. Nasdaq delisting risk looms from filing delays. Yet cash stays tight.
10-Q
Q2 FY2025 results
Celularity's Q2 FY2025 revenues fell 52.6% y/y to $5.7M, driven by a 76.1% drop in product sales to $2.4M amid lower Biovance 3L demand, though license and royalty income rose 139.3% to $2.1M from distribution deals. Gross margins contracted sharply as cost of revenues surged 147% to $5.2M, including $1.8M in bulk material write-offs and $1.2M Rebound milestone payments, yielding an operating loss of $15.9M, up 55.9% y/y. YTD, revenues declined 35.9% to $17.2M with operating loss widening 50.1% to $26.4M; diluted EPS of $(1.86) aligns with 23.8M weighted shares. Cash dipped to $0.9M from $0.7M, with $43.4M total debt under forbearance and $10.1M restricted cash; free cash flow not disclosed in the 10-Q. Yet the biomaterials pivot shows promise. Nasdaq delisting risk looms if filings lag.
8-K
Celularity retires all debt
Celularity sold intellectual property assets to Celeniv for $33.8 million on August 13, 2025, using proceeds to retire $27 million in debt to RWI and $6.8 million to Mr. Lim, wiping out all senior secured obligations. It licensed back exclusive rights for five years, with quarterly royalties and a five-year repurchase option at a mid-eight-figure price. Debt-free, Celularity restructured into subsidiaries for biomaterials, longevity therapy, biobanking, and manufacturing. Balance sheet strengthened, yet royalties loom.
AURX
Nuo Therapeutics, Inc.
2.29+0.00
BRTX
BioRestorative Therapies, Inc.
1.56-0.09
CCEL
Cryo-Cell International, Inc.
4.40-0.11
CELC
Celcuity Inc.
74.00-0.44
CELZ
Creative Medical Technology Hol
3.76-1.83
CLLS
Cellectis S.A.
3.63+0.05
FBLG
FibroBiologics, Inc.
0.39-0.03
MESO
Mesoblast Limited
16.36-0.37
PLUR
Pluri Inc.
3.76-0.25
VCEL
Vericel Corporation
34.88-1.95